CD8A and female reproductive organ cancer: Collectively, these findings weave a cohesive narrative: HDACs suppress antitumor immunity in gynecological cancers by altering the TIME, while HDACi counteract this by enhancing antigen presentation, invigorating CD8 + T-cell responses, and destabilizing immunosuppressive networks (Fig. 1).